Valneva announces u.s. fda approval of world's first chikungunya vaccine, ixchiq®

Saint-herblain (france), november 10, 2023 – valneva se (nasdaq: valn; euronext paris: vla), a specialty vaccine company, today announced that the u.s. food and drug administration (fda) has approved ixchiq®, valneva's single-dose, live-attenuated vaccine indicated for the prevention of disease caused by chikungunya virus (chikv) in individuals 18 years of age and older who are at increased risk of exposure to chikv. this indication is approved under accelerated approval based on anti-chikv neutralizing antibody titers. continued approval for this indication is contingent upon verification of clinical benefit in confirmatory studies.
VALN Ratings Summary
VALN Quant Ranking